Boehringer Ingelheim USA Corporation

FIBRONEER™-IPF trial met primary endpoint: absolute change in Forced Vital Capacity at week 52. Boehringer Ingelheim to submit nerandomilast for IPF treatment to FDA and other health authorities. Full data to be presented in 2025.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

A.A. (UCSF, NIH T32 grant, past consulting income from LeMaitre and MIS Technologies) and D.R. (FDA) have no conflicts of interest. L.H.C. (Duke, FDA, past consulting income from Regeneron, NFLPA, Boehringer, institutional grants from GSK, Novartis) also has no conflicts. R.M.C. (FDA, former Verily Life Sciences, Google Health employee, held equity, served on boards of Cytokinetics, Centessa, Clinetic, Keystone Symposia, C-Path, Clinical Research Forum, One Fifteen) discloses no conflicts related to this manuscript.

At EASD 2024, Boehringer Ingelheim's survodutide, a GCGR/GLP-1R dual agonist, showed 40% of overweight/obese patients achieved >20% weight loss after 46 weeks, with no plateau. For MASH, it reduced blood pressure significantly. Safety concerns were due to rapid dose escalation, which could be mitigated by gradual escalation. No direct correlation between amino acid levels and muscle loss was found. Key opinion leaders find a GCGR/GLP-1R dual agonist desirable for weight, glucose, and blood pressure reduction, improving lipids, and sustaining metabolic rate.

The weight-loss treatment market is expected to see 16 new drugs by 2029, expanding the market to $200 billion by 2031, driven by interest sparked by Novo Nordisk and Eli Lilly. Amgen and Pfizer are among companies testing their drug candidates, which could lower prices amid criticism over high costs.

PhoreMost Ltd secured an additional €10.8m to advance oncology and inflammation degrader programmes and its AI-supported GlueSEEKER™ platform for novel molecular glue degraders.

OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® in second-line NSCLC, targeting HLA-A2+ patients with secondary resistance to ICI, aiming for regulatory registration in Europe and North America.